Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms
about
Insights into Chemoresistance of Prostate CancerMetronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung CancerCisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapySmall molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cellsResidual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity.The role of epithelial plasticity in prostate cancer dissemination and treatment resistanceKinetics of MDR transport in tumor-initiating cells.Understanding cancer stem cell heterogeneity and plasticity.Targeted therapy against cancer stem cells.Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancerDrug-resistant colon cancer cells produce high carcinoembryonic antigen and might not be cancer-initiating cellsRecent advances in the ARID family: focusing on roles in human cancer.Metronomics: towards personalized chemotherapy?Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer.The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells.Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.Epigenetic Targeting of Glioblastoma
P2860
Q26795589-2968E6F6-F554-490D-B1C5-B63109E5890DQ27015786-C3444EE5-A6D7-4D07-8EB8-4C832B01C2A9Q33615709-21FBEE13-BB67-446B-8712-C1C8496C3944Q33798642-45EBC7CD-BC03-48AD-86F2-D290D21A1940Q34463435-D105B896-EEC9-4209-A735-2F566578DDE8Q34505037-05620827-727C-4324-8E80-64463538C727Q35041207-0104BA9A-2E74-418D-AD8D-2D62773B85C9Q35796886-3BD776BF-49D1-4F6D-B169-248DB629CC0DQ35802983-69AAE35F-7ADA-4C08-A26E-0F6629574A63Q36910062-4B2B42CD-8525-4F68-8C1B-CB1754A7F5EDQ36957616-9A995CAA-166B-4CE5-86B3-B1C25E22B0FDQ37601383-8D525E62-C14B-4349-935D-3629DC4D06EBQ38218923-83BB6CE1-64F8-4E89-A858-3F93DC2ED975Q38783511-68A6ADD4-81BB-4CF6-9EAC-58C3584D3FC7Q38819651-FE758EDA-A4EE-4D52-B7BC-0198610A42B7Q39112034-6A27AF6B-882C-4380-8C27-1EDFB997C282Q48288989-BB1FCE7B-B25B-40B9-BF66-8CC79DE37C0AQ58554073-B13AAF47-A5CB-4F6C-83F7-95EC48D0AF87
P2860
Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@ast
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@en
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@nl
type
label
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@ast
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@en
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@nl
prefLabel
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@ast
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@en
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@nl
P2093
P2860
P1433
P1476
Drug-tolerant cancer cells sho ...... ence for epigenetic mechanisms
@en
P2093
Dean G Tang
Hangwen Li
Izabela Fokt
Jim Klostergaard
Luis Della Coletta
Qiuping Zhang
Stanislaw Skora
Tammy Calhoun-Davis
P2860
P304
P356
10.1371/JOURNAL.PONE.0024397
P407
P50
P577
2011-09-15T00:00:00Z